Side-by-side comparison of AI visibility scores, market position, and capabilities
NASDAQ-listed (GDRX) prescription savings platform comparing prices across 70K+ pharmacies; $750M revenue with stock under pressure from Amazon Pharmacy and Cost Plus Drugs competition.
GoodRx is a Santa Monica-based prescription savings and healthcare price comparison platform that enables consumers to compare prices, access discount coupons, and find the lowest-cost pharmacy for their prescriptions — providing free price comparison tools across 70,000+ US pharmacies and a GoodRx Gold subscription ($9.99/month) with even lower prices on 1,000+ common medications. Listed on NASDAQ (NASDAQ: GDRX), GoodRx went public in September 2020 and generates approximately $750 million in annual revenue primarily from pharmaceutical industry fees and consumer subscription revenue.
mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.